Author of

• 10801

  +

  P1.11 - Poster Session 1 - NSCLC Novel Therapies (ID 208)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10806

    +

    P1.11-005 - EVEREST Study: Evolution of disease-related symptoms of patients (p) with advanced non-small cell lung cancer (NSCLC) and its correlation with response to first-line (1L) treatment. (ID 3277)

    09:30 - 09:30  |  Author(s): Y.S. Afonzo Gobbi
    • Abstract

    Background
    The control of symptoms to maintain the health-related quality of life continues to be a priority in the treatment of advanced NSCLC. The aim of our study was to assess the evolution of the disease-related symptoms and, due to the lack of evidence, to evaluate its correlation with the response to 1L treatment in p with advanced NSCLC.

    Methods
    EVEREST is an observational prospective study carried out in 33 Spanish institutions. A total of 155 p with advanced NSCLC initiating standard platinum-based 1L treatment were included. Disease-related symptoms were assessed at baseline and after completing 4-6 cycles of 1L treatment (final visit) with the Lung Cancer Symptom Scale (LCSS) and an ad-hoc specific questionnaire evaluating their frequency. Response to treatment was assessed according to RECIST criteria.

    Results
    Baseline characteristics of the 155 p enrolled were: 76.1% male, 96.1% Caucasian, 70.3% adenocarcinoma, 16.8% squamous-cell carcinoma; median age was 62 years. ECOG PS 0/1/2: 26.5%/54.8%/14.8%. 65.3% and 12.9% of p maintained or improved the ECOG status during the study, respectively. 118 p completed at least 4 cycles of treatment. Best response to 1L treatment was: 1.7% complete response, 68.4% partial response and 26.5% stable disease. Most frequent disease-related symptoms were asthenia and pain. 1L treatment did not deteriorate disease-related symptoms compared to baseline (LCSS score was reduced 1.4 points) and an improvement in cough was observed (p=0.026). The frequency of cough (p<0.001), dyspnea (p=0.025), pain (p=0.009) and discomfort (p=0.034) were significantly reduced. No significant correlation with response to treatment and the evolution of symptomology between visits was found.

    Conclusion
    1L treatment was associated with a reduction of the frequency (cough, dyspnea, pain and discomfort) and intensity (cough) of disease-related symptoms in p with advanced NSCLC, irrespective of the response achieved.